NEURALSTEM, INC. |
End-of-day quote
Other stock markets
|
||
| - USD | - |
|
| Sales 2024 * | - | Sales 2025 * | - | Capitalization | 4.25M 355M |
|---|---|---|---|---|---|
| Net income 2024 * | -14M -1.17B | Net income 2025 * | -19M -1.59B | EV / Sales 2024 * | - |
| Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | - |
| P/E ratio 2024 * |
-0.39
x | P/E ratio 2025 * |
-0.52
x | Employees | - |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 0% |
More Fundamentals
* Assessed data
More news
More recommendations
More press releases
| Managers | Title | Age | Since |
|---|---|---|---|
| - | - | ||
| - | - | ||
| 73 | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| 65 | - | ||
| 66 | - | ||
Bin Xian Wei
BRD | Director/Board Member | 54 | 05/19/05 |
Seneca Biopharma, Inc., formerly Neuralstem, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing treatments for diseases of unmet medical need. It is focused on finding and acquiring new assets, sciences and technologies that provide therapies for patients. It intends to focus on developing a pipeline of biopharmaceuticals and commercializing those products.
Sector
-
Calendar
17/06/2024
- Virtual Investor Pitch Conference
